Neurophth is China's first gene therapy company for ophthalmic diseases.
Neurophth is China's first gene therapy company for ophthalmic diseases. As a clinical-stage company, Neurophth is dedicated to discovering and developing gene therapies for patients suffering from blindness and other eye diseases globally.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Apr 8, 2020 | Series A | ¥130M | 1 | Fosun International | — | Detail |
Jan 1, 2018 | Angel | — | 1 | Qiji Zhiguang Fund | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Fosun International | Yes | Series A |
Qiji Zhiguang Fund | Yes | Angel |